Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Karuna Therapeutics, Inc. is conducting a Phase 3 global, multicenter, open-label extension study titled ‘ADEPT-3’ to evaluate the long-term safety and tolerability of KarXT in individuals with psychosis associated with Alzheimer’s Disease. This study is significant as it aims to provide insights into the sustained use of KarXT, potentially offering a new therapeutic option for this challenging condition.
The intervention being tested is KarXT, a drug composed of Xanomeline and Trospium Chloride, designed to manage psychosis symptoms in Alzheimer’s patients. The study tests various dosages to determine the optimal balance of efficacy and safety.
The study follows an interventional design with a single-group model, meaning all participants receive the treatment. There is no masking, which means both researchers and participants know the treatment being administered. The primary purpose of the study is treatment-focused.
The study began on July 11, 2023, with an estimated completion date in August 2025. These dates are crucial as they guide investors on the timeline for potential data releases and regulatory submissions.
This study update could positively impact Karuna Therapeutics’ stock performance, as successful results may enhance the company’s market position in the Alzheimer’s treatment space. Investors should also consider the competitive landscape, as advancements in this area are highly sought after.
The study is currently ongoing, with further details available on the ClinicalTrials portal.